BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Surefire Medical, Inc.'s Infusion System for Embolization Procedures Receives CE Mark Approval


9/5/2012 7:23:36 AM

WESTMINSTER, Colo., Sept. 5, 2012 /PRNewswire/ -- European regulators have approved Surefire Medical's Surefire Infusion System, a next generation device for chemo- and radioembolization procedures. The Colorado-based medical device company today announced that it is launching this product in the European market immediately.

"Surefire Medical developed this ground-breaking technology to provide interventional radiologists with improved embolization certainty during their infusion procedures," said Jim Chomas, CEO of Surefire Medical. "With the CE Mark approval, we are able to introduce the Surefire Infusion System, which may offer substantial advantages over a standard microcatheter, throughout Europe."

Clinical results
In a recent retrospective study of 29 patients, infusion of therapeutic agent with the Surefire Infusion System showed no angiographic evidence of reflux and no clinical evidence of non-target embolization. CT imaging in chemoembolization patients suggested a pattern of increased microsphere tumor penetration and contrast retention.1

Additionally, the Surefire High-Flow Microcatheter System recently received U.S. FDA 510(k) clearance. The Surefire Infusion System received FDA 510(k) clearance in June 2011.

As part of the international launch, Surefire Medical will participate in the upcoming annual meeting of the Cardiovascular and Interventional Radiological Society of Europe 2012 in Lisbon, Portugal.

1J. D. Louie, E. A. Wang, S. Broadwell, B. C. Wible, A. Arepally, C. Nutting, L. Bester, D. Y. Sze. First in Man Experience with the Surefire Infusion System A dedicated microcatheter system to eliminate reflux during embolotherapy. Presented during Society of Interventional Radiology Annual Scientific Meeting, March 2012.

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to increase embolization efficiency, minimize reflux and reduce damage to healthy tissue. For more information, please visit www.surefiremedical.com.

SOURCE Surefire Medical, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->